Insider Selling: Voyager Therapeutics (NASDAQ:VYGR) Insider Sells $13,571.25 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Todd Alfred Carter sold 3,525 shares of the firm’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $3.85, for a total transaction of $13,571.25. Following the completion of the sale, the insider owned 153,193 shares of the company’s stock, valued at $589,793.05. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Voyager Therapeutics Trading Down 0.9%

Shares of NASDAQ VYGR opened at $3.39 on Friday. The firm has a market capitalization of $188.48 million, a P/E ratio of -1.57 and a beta of 1.30. The firm’s 50-day moving average price is $3.99 and its 200-day moving average price is $4.08. Voyager Therapeutics, Inc. has a 1-year low of $2.64 and a 1-year high of $5.55.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors have recently bought and sold shares of the stock. Privium Fund Management B.V. raised its position in Voyager Therapeutics by 16.6% in the 2nd quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock valued at $79,000 after buying an additional 3,596 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Voyager Therapeutics by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 61,775 shares of the company’s stock worth $249,000 after acquiring an additional 5,422 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Voyager Therapeutics by 1.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company’s stock worth $1,191,000 after acquiring an additional 5,560 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after purchasing an additional 6,748 shares during the last quarter. Finally, Jain Global LLC raised its holdings in shares of Voyager Therapeutics by 44.1% in the third quarter. Jain Global LLC now owns 28,104 shares of the company’s stock valued at $131,000 after purchasing an additional 8,600 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on VYGR. HC Wainwright reduced their price objective on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Finally, Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Voyager Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $13.75.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.